{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:35:31Z","timestamp":1780090531905,"version":"3.54.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["POIR.04.02.00-00-D001\/20"],"award-info":[{"award-number":["POIR.04.02.00-00-D001\/20"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001870","name":"Foundation for Polish Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017150","name":"CALIPSOplus","doi-asserted-by":"publisher","award":["730872"],"award-info":[{"award-number":["730872"]}],"id":[{"id":"10.13039\/100017150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["UMO- 2020 \/39\/D\/ST4\/01344"],"award-info":[{"award-number":["UMO- 2020 \/39\/D\/ST4\/01344"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["UMO-2021\/42\/E\/NZ7\/00422"],"award-info":[{"award-number":["UMO-2021\/42\/E\/NZ7\/00422"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118652","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:27:28Z","timestamp":1770395248000},"page":"118652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["N-terphenylpicolinamide derivatives designed to target PD-L1 increase activation and proliferation of T cells, and their cytotoxic properties toward cancer cells"],"prefix":"10.1016","volume":"307","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-382X","authenticated-orcid":false,"given":"Damian","family":"Muszak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kocik-Krol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Zaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Kruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Palej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Fijolkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Maslanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Magiera-Mularz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Plewka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Stec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Surmiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Szafarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Siedlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Musielak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Kitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Wyska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Skalniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Surmiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118652_bib1","first-page":"451","article-title":"Global cancer statistics 2022: the trends projection analysis","volume":"10","author":"Chhikara","year":"2023","journal-title":"Chem. Biol. Lett."},{"key":"10.1016\/j.ejmech.2026.118652_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118652_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/d41586-018-06751-0","article-title":"Cancer immunologists scoop medicine nobel prize","volume":"562","author":"Ledford","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118652_bib4","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2026.118652_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmmed.2023.1140977","article-title":"Cancer immunotherapies: a hope for the uncurable?","volume":"3","author":"Hamdan","year":"2023","journal-title":"Frontiers in Molecular Medicine"},{"key":"10.1016\/j.ejmech.2026.118652_bib6","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2026.118652_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2026.118652_bib8","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118652_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118652_bib10","first-page":"1","article-title":"Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy","volume":"10","author":"Ju","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118652_bib11","article-title":"Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.118652_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118652_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118652_bib14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118652_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111876","article-title":"Progress in PD-1\/PD-L1 pathway inhibitors: from biomacromolecules to small molecules","volume":"186","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib16","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00044-023-03127-6","article-title":"Progress on biphenyl derivatives as PD-1\/PD-L1 inhibitors","volume":"32","author":"Wang","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.118652_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113170","article-title":"Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1\/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation","volume":"213","author":"Pan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/13543776.2022.2045276","article-title":"Small molecule inhibitors of programmed cell death ligand 1 (PD-L1): a patent review (2019\u20132021)","volume":"32","author":"Deng","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118652_bib19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/13543776.2024.2368237","article-title":"An updated patent review on PD-1\/PD-L1 antagonists (2022-present)","volume":"34","author":"Uzar","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118652_bib20","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3390\/molecules24112071","article-title":"Development of the inhibitors that target the PD-1\/PD-L1 interaction\u2014A brief look at progress on small molecules, peptides and macrocycles","volume":"24","author":"Guzik","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118652_bib21","series-title":"Macrocyclic Inhibitors of the pd-1\/pd-l1 and cd80(b7-1)\/pd-l1 protein\/protein Interactions","author":"Miller","year":"2014"},{"key":"10.1016\/j.ejmech.2026.118652_bib22","series-title":"Compounds Useful as Immunomodulators","author":"Chupak","year":"2015"},{"key":"10.1016\/j.ejmech.2026.118652_bib23","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.1021\/acs.jmedchem.1c00392","article-title":"Syntheses, biological evaluations, and mechanistic studies of Benzo[c][1,2,5]oxadiazole derivatives as potent PD-L1 inhibitors with in vivo antitumor activity","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib24","doi-asserted-by":"crossref","first-page":"16020","DOI":"10.1021\/acs.jmedchem.1c01409","article-title":"Interfering with the tumor-immune interface: making way for triazine-based small molecules as novel PD-L1 inhibitors","volume":"64","author":"Russomanno","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib25","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.1021\/acs.jmedchem.0c00574","article-title":"Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell Death-1\/Programmed cell death-ligand 1 interaction as potential anticancer agents","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib26","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41467-021-21410-1","article-title":"Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1","volume":"12","author":"Park","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118652_bib27","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/2159-8290.CD-21-1156","article-title":"Characterization of INCB086550: a potent and novel small-molecule PD-L1 inhibitor","volume":"12","author":"Koblish","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118652_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008547","article-title":"Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors","volume":"12","author":"Odegard","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2026.118652_bib29","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.118652_bib30","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1021\/acs.jmedchem.7b00293","article-title":"Small-molecule inhibitors of the programmed cell Death-1\/Programmed death-ligand 1 (PD-1\/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1","volume":"60","author":"Guzik","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01853-4","article-title":"Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies","volume":"22","author":"Rodriguez","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118652_bib32","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1016\/j.apsb.2022.04.007","article-title":"Novel phthalimides regulating PD-1\/PD-L1 interaction as potential immunotherapy agents","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.118652_bib33","doi-asserted-by":"crossref","first-page":"16807","DOI":"10.1021\/acs.jmedchem.3c01534","article-title":"Discovery of novel PD-L1 inhibitors that induce the dimerization, internalization, and degradation of PD-L1 based on the fragment coupling strategy","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib34","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.5c00245","article-title":"Characterization of clinically evaluated small-molecule inhibitors of PD-L1 for immunotherapy","author":"Slota","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118652_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117141","article-title":"Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020\u20132024)","volume":"283","author":"Cheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib36","doi-asserted-by":"crossref","first-page":"11614","DOI":"10.1021\/acs.jmedchem.1c00957","article-title":"Terphenyl-based small-molecule inhibitors of programmed cell Death-1\/Programmed death-ligand 1 protein-protein interaction","volume":"64","author":"Muszak","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib37","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.3390\/molecules29112646","article-title":"C2-Symmetrical terphenyl derivatives as small molecule inhibitors of programmed cell death 1\/Programmed death ligand 1 protein\u2013protein interaction","volume":"29","author":"Klimek","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118652_bib38","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1021\/acs.jmedchem.1c00010","article-title":"Novel biphenyl pyridines as potent small-molecule inhibitors targeting the programmed cell Death-1\/Programmed cell death-ligand 1 interaction","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113637","article-title":"Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1\/programmed cell death-ligand 1 interaction","volume":"223","author":"Wu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib40","series-title":"Pochodne 6-(2-chloro-[1,1\u2019-bifenyl]-3-ylo)benzo-1,4-dioksanu Do Stosowania W Immunoterapii Nowotwor\u00f3w","author":"Muszak","year":"2020"},{"key":"10.1016\/j.ejmech.2026.118652_bib41","series-title":"Triaryl Compounds for Treatment of PD-L1 Diseases","author":"Fan","year":"2020"},{"key":"10.1016\/j.ejmech.2026.118652_bib42","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.1158\/1538-7445.AM2015-5440","article-title":"Abstract 5440: novel PD-1 blockade bioassay to assess therapeutic antibodies in PD-1 and PD-L1 immunotherapy programs","volume":"75","author":"Cheng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118652_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1021\/acsmedchemlett.3c00306","article-title":"Solubilizer tag effect on PD-L1\/Inhibitor binding properties for m -Terphenyl derivatives","volume":"15","author":"Surmiak","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118652_bib44","series-title":"IMMUNO-Model in Cancer: Methods and Protocols","first-page":"85","article-title":"A PD-1\/PD-L1-Sensitive co-culture-based primary T-Cell activation assay","author":"Kocik-Krol","year":"2026"},{"key":"10.1016\/j.ejmech.2026.118652_bib45","article-title":"Macrocyclic peptide inhibitor of PD\u20101\/PD\u2010L1 immune checkpoint","volume":"4","author":"Magiera\u2010Mularz","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2026.118652_bib46","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1021\/acs.jmedchem.1c01682","article-title":"Discovery of small-molecule inhibitors of the PD-1\/PD-L1 axis that promote PD-L1 internalization and degradation","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib47","article-title":"A small molecule antagonist of PD-1\/PD-L1 interactions acts as an immune checkpoint inhibitor for NSCLC and melanoma immunotherapy","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118652_bib48","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/acs.jmedchem.4c01640","article-title":"Novel PD-L1\/VISTA dual inhibitor as potential immunotherapy agents","volume":"68","author":"Sun","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib49","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1021\/acs.jmedchem.3c02362","article-title":"Discovery of highly potent small-molecule PD-1\/PD-L1 inhibitors with a novel scaffold for cancer immunotherapy","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101960","article-title":"Human and mouse PD-L1: similar molecular structure, but different druggability profiles","volume":"24","author":"Magiera-Mularz","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2026.118652_bib51","doi-asserted-by":"crossref","first-page":"16789","DOI":"10.1073\/pnas.0407607101","article-title":"Halogen bonds in biological molecules","volume":"101","author":"Auffinger","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118652_bib52","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1021\/acs.jmedchem.2c02015","article-title":"\u201cMagic Chloro\u201d: profound effects of the chlorine atom in drug discovery","volume":"66","author":"Chiodi","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118868","article-title":"Balancing cell cycle arrest and immune activation: a synergistic window for idasanutlin and anti-PD-1 therapy in a syngeneic mouse model","volume":"193","author":"Nieznanska","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.118652_bib54","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.118652_bib55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2010.09.020","article-title":"T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells","volume":"362","author":"Leitner","year":"2010","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejmech.2026.118652_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129882","article-title":"N-methylmorpholine incorporation into the structure of biphenyl leads to the bioactive inhibitor of PD-1\/PD-L1 interaction","volume":"110","author":"Zaber","year":"2024","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118652_bib57","doi-asserted-by":"crossref","first-page":"14879","DOI":"10.1021\/acs.joc.2c01649","article-title":"Protoboration of alkynes and Miyaura borylation catalyzed by low loadings of palladium","volume":"87","author":"Xu","year":"2022","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib58","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1021\/ol5028738","article-title":"A catalytic borylation\/dehalogenation route to o-Fluoro arylboronates","volume":"16","author":"Jayasundara","year":"2014","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2026.118652_bib59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/jm500305p","article-title":"Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis","volume":"58","author":"Lou","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib60","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.jmedchem.0c01698","article-title":"Discovery of BMS-986202: a clinical Tyk2 inhibitor that binds to Tyk2 JH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118652_bib61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1021\/jm051065l","article-title":"Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABAA\u03b12\/\u03b13 binding site agonists for the treatment of anxiety disorders","volume":"49","author":"Goodacre","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:09:23Z","timestamp":1777529363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":61,"alternative-id":["S0223523426000978"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118652","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-terphenylpicolinamide derivatives designed to target PD-L1 increase activation and proliferation of T cells, and their cytotoxic properties toward cancer cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118652"}}